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Abstract
This report describes the structure, function, and tissue distribution pattern of rat OCTN1 (novel organic cation
transporter 1). The rat OCTN1 cDNA was isolated from a rat placental cDNA library. The cDNA is 2258 bp long and codes
for a protein of 553 amino acids. Its amino acid sequence bears high homology to human OCTN1 (85% identity) and rat
OCTN2 (74% identity). When expressed heterologously in mammalian cells, rat OCTN1 mediates Na-independent and pH-
dependent transport of the prototypical organic cation tetraethylammonium. The transporter interacts with a variety of
structurally diverse organic cations such as desipramine, dimethylamiloride, cimetidine, procainamide, and verapamil.
Carnitine, a zwitterion, interacts with rat OCTN1 with a very low affinity. However, the transport of carnitine via rat
OCTN1 is not evident in the presence or absence of Na. We conclude that rat OCTN1 is a multispecific organic cation
transporter. OCTN1-specific mRNA transcripts are present in a wide variety of tissues in the rat, principally in the liver,
intestine, kidney, brain, heart and placenta. In situ hybridization shows the distribution pattern of the transcripts in the brain
(cerebellum, hippocampus and cortex), kidney (cortex and medulla with relatively more abundance in the cortical-medullary
junction), heart (myocardium and valves) and placenta (labyrinthine zone). ß 2000 Elsevier Science B.V. All rights
reserved.
Keywords: Organic cation transport; OCTN1; Carnitine; Drug disposition; In situ hybridization; (Rat)
1. Introduction
Ionic compounds, which are present endogenously
or obtained exogenously (xenobiotics), present a
complex problem to the body’s mechanisms of clear-
ance and metabolism because of the diverse structure
of these compounds. Recent studies have de¢ned a
family of multispeci¢c organic ion transporters re-
sponsible for the carrier-mediated clearance of a
wide range of structurally diverse xenobiotics and
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endobiotics [1,2]. Most of these transporters are ex-
pressed primarily in the kidney, liver and intestine,
the tissues involved in drug elimination. The mem-
bers of this family include the organic cation trans-
porter (OCT)1 [3], OCT2 [4], OCT3 [5], novel organ-
ic cation transporter (OCTN)1 [6], OCTN2 [7], and
the organic anion transporter (OAT)1 [8,9], OAT2
[10], OAT3 [11] and OAT4 [12].
OCTN1 was originally cloned from human fetal
kidney [6]. In contrast to OCTs and OATs that ex-
hibit a restricted tissue distribution pattern, OCTN1
is expressed in a wide variety of tissues and cell lines
of human origin [6]. The transport characteristics of
hOCTN1 include multispeci¢c, bidirectional organic
cation transport in a pH-dependent manner [13]. It
has been hypothesized that this transporter is respon-
sible for the e¥ux of organic cations across the renal
brush border membrane via the organic cation/H
antiport mechanism [13]. This is interesting because
OCT1^3 are potential-sensitive transporters. H does
not play any direct role in the transport mechanism
of these transporters. hOCTN1 exhibits the highest
homology in amino acid sequence to hOCTN2 [7]
and relatively much lower homology to OCTs and
OATs. Interestingly, OCTN2 is an Na-dependent
transporter for the zwitterions carnitine and acylcar-
nitines and an Na-independent transporter for sev-
eral organic cations [14,15]. Thus, OCTN1 appears
to be unique among the members of the organic ion
transporter family due to its postulated function as
an organic cation/H antiporter [13].
Our laboratory has been interested for several
years in the transport function of placenta, an organ
that plays an obligatory role in the development of
the fetus. Placenta expresses several transporters that
mediate the delivery of essential nutrients from the
mother to the fetus. In addition, this tissue is also
involved in drug elimination, a function that is very
important to protect the developing fetus from phar-
macologically active drugs that might be present in
the maternal circulation. Therefore, identi¢cation
and characterization of the drug transport systems
expressed in the placenta is clinically very relevant.
We have recently cloned OCT3 and OCTN2 from
placenta or placental cell lines [5,7]. Here we report
the cloning and functional characterization of
OCTN1 from rat placenta. We also show that
OCTN1 mRNA is expressed in a wide variety of
tissues in the rat as assessed by Northern blot anal-
ysis and by in situ hybridization.
2. Materials and methods
2.1. Materials
[ethyl-1-14C]Tetraethylammonium (TEA) bromide
(speci¢c activity 55 mCi/mmol) was obtained from
American Radiolabeled Chemicals, Inc. (St. Louis,
MO, USA). L-[3H]Carnitine (speci¢c activity 65 Ci/
mmol) was obtained from Moravek Biochemicals,
Inc. (Brea, CA, USA). Unlabeled organic cations
and carnitine were obtained from Research Biochem-
icals International (Natick, MA, USA) or Sigma.
Cell culture media and lipofectin were obtained
from Life Technologies, Inc. (Gaithersburg, MD,
USA). Restriction enzymes were obtained from
Promega (Madison, WI, USA). Magna nylon trans-
fer membranes were purchased from Micron Separa-
tions, Inc. (Westboro, MA, USA). Human retinal
pigment epithelial (HRPE) cells were originally pro-
vided by Dr. M.A. Del Monte (University of Mich-
igan, Ann Arbor, MI, USA) and have been in use in
our laboratory for several years [16]. The Ready-to-
go oligolabeling kit used in the preparation of cDNA
probes for library screening was purchased from
Amersham Pharmacia Biotech (Piscataway, NJ,
USA).
2.2. Reverse transcription-polymerase chain reaction
(RT-PCR) and probe preparation
Total RNA was isolated from JAR cells (a human
placental trophoblast cell line) with Trizol reagent
(Life Technologies) according to manufacturer’s pro-
tocol. Poly(A) RNA was then prepared by a⁄nity
chromatography on an oligo dT-cellulose column
(Life Technologies). The integrity of the RNA sam-
ple was checked by formaldehyde^agarose gel elec-
trophoresis. A pair of PCR primers speci¢c for the
hOCTN1 cDNA was designed: 5P-caccacctccctgttctt-
3P (forward primer) and 5P-atgatgctgcccactctg-3P (re-
verse primer). Primers were based upon the pub-
lished sequence of hOCTN1 and correspond to nu-
cleotide positions 578^595 and 1550^1567 in
hOCTN1 cDNA [6]. RT-PCR was conducted using
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JAR cell poly(A) RNA with Geneamp RNA-PCR
kit (Perkin Elmer). The RT-PCR reaction product
was run on a 1% agarose gel for determination of
the size of the product. A V1.0 kbp product, ex-
pected on the basis of the positions of the primers,
was obtained. This product was excised from the gel
and gene-cleaned. The product was then cloned into
pGEM-T vector (Promega) and the cDNA insert was
sequenced by the dideoxynucleotide chain termina-
tion method for con¢rmation of its identity.
2.3. Screening of cDNA library
The Superscript Plasmid System (Life Technolo-
gies) was used to establish the directional cDNA li-
brary using the poly(A) RNA isolated from rat
placenta. The V1.0 kbp fragment of hOCTN1
cDNA, obtained by RT-PCR, was used to screen
the rat placental cDNA library [17,18]. The probe
was labeled with [K-32P]dCTP using the Ready-to-
go oligolabeling kit. The cDNA library was screened
at low stringency conditions as described [17,18]. Hy-
bridization was carried out for 20 h at 60‡C in a
solution containing 5Usaline^sodium phosphate^
EDTA (SSPE) (1USSPE = 0.15 M NaCl, 10 mM
NaH2PO4, and 1 mM EDTA), 5UDenhardt’s solu-
tion, 0.5% SDS and 100 Wg/ml denatured salmon
sperm DNA. Posthybridization washing involved ex-
tensive washes with 3USSPE/0.5% sodium dodecyl
sulfate (SDS) at room temperature. Positive clones
were identi¢ed, and the colonies were puri¢ed by
secondary screening.
2.4. DNA sequencing
Sense and antisense strands of the cDNAs were
both sequenced by primer walking. Sequencing by
the dideoxynucleotide chain termination method
was performed by Taq DyeDeoxy terminator cycle
sequencing with an automated Perkin-Elmer Applied
Biosystems 377 Prism DNA sequencer.
2.5. Functional expression of rat OCTN1 cDNA in
HRPE cells
The cloned rat OCTN1 cDNA was oriented in the
pSPORT plasmid in such a way that its expression
was under the control of the T7 promoter. The
cDNA was heterologously expressed in HRPE cells
by the vaccinia virus expression system as described
[5,7]. Transport measurements were made at room
temperature using [14C]TEA or [3H]carnitine as sub-
strates. The transport bu¡er was composed of
25 mM Tris/HEPES (pH 8) or 25 mM HEPES/Tris
(pH 7.5) supplemented with 140 mM NaCl (or 140
mM N-methyl-D-glucamine chloride), 5.4 mM KCl,
1.8 mM CaCl2, 0.8 mM MgSO4, and 5 mM glucose.
After incubation for 30 min at 37‡C, transport was
terminated by aspiration of the bu¡er followed by
two washes with 2 ml of ice-cold transport bu¡er.
The cells were then solubilized with 0.5 ml of 1%
SDS in 0.2 NaOH and transferred to vials for quan-
titation of the radioactivity associated with the cells.
HRPE cells transfected with vector alone under sim-
ilar conditions served as control.
2.6. In situ hybridization
Four weeks old male rat kidney, heart and whole
brain were collected and immediately frozen in liquid
nitrogen. Additionally, rat term placentas were also
collected and frozen. Un¢xed 12 Wm serial sections
were prepared on a cryostat, mounted on 2% 3-ami-
nopropyltriethyloxysilane-coated slides, air dried for
10 min, and stored at 370‡C until required. Non-
radioactive in situ hybridization using digoxigenin
UTP-labeled probes was performed on tissue sections
as described previously [15,19]. Cryostat sections
were ¢xed in 4% paraformaldehyde in 0.1 M phos-
phate-bu¡ered saline (PBS) (pH 7.3) at 4‡C for
20 min, washed, and permeabilized with proteinase
K (10 Wg/ml in PBS containing 0.1% Tween 20) for
10 min at room temperature. Sections were then re-
¢xed in 4% paraformaldehyde in PBS, prehybridized
for 1 h at 65‡C in 50% formamide, and incubated
with sense and antisense riboprobes for 16 h at 65‡C.
For immunologic detection of the probe, sections
were incubated for 2 h with alkaline phosphatase-
coupled anti-digoxigenin antibody and color reaction
was developed using a commercially available chro-
mogenic kit (Boehringer-Mannheim, Indianapolis,
IN, USA). For the preparation of the rOCTN1-spe-
ci¢c riboprobes, a 0.85 kbp fragment of the rOCTN1
cDNA, obtained through the digestion of pSPORT-
rOCTN1 cDNA by StyI, was subcloned into the
pBluescript vector. The orientation of the cDNA in-
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sert in the pBluescript vector was determined by se-
quencing. Antisense and sense riboprobes were syn-
thesized with T7 RNA polymerase or T3 RNA poly-
merase after linearization of the plasmid with
appropriate restriction enzymes. The riboprobes
were labeled using a digoxigenin-labeling kit (Boehr-
inger-Mannheim, Indianapolis, IN, USA).
2.7. Northern blot analysis
A hybridization ready multiple tissue blot contain-
ing size-fractionated poly(A) RNA from 12 di¡er-
ent rat tissues was purchased from Origene (Rock-
ville, MD, USA). This blot was probed sequentially
under high stringency conditions using 32P-labeled
rat OCTN1 cDNA and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) cDNA as probes.
2.8. Data analysis
Each uptake experiment was done in duplicate or
triplicate and repeated two or three times. Uptake
values given are means þ S.E.M. of these replicates.
The dose^response data for various inhibitors were
analyzed by a non-linear regression method using the
computer program Sigma Plot (SPSS Inc., Chicago,
IL, USA).
3. Results
3.1. Structural features of rOCTN1
Using a V1.0 kbp fragment of human OCTN1
cDNA obtained by RT-PCR, we screened a rat pla-
cental cDNA library. Several positive clones were
obtained. The cDNA inserts of these clones were
initially characterized by restriction fragment analy-
sis and nucleotide sequencing of the 5P-ends. These
analyses showed that the positive clones consisted of
two di¡erent cDNA inserts. One of these was found
to be the rat homolog of human OCTN1 and the
other to be rat homolog of human OCTN2 [15].
The rat OCTN1 clones contained cDNA inserts of
C
Fig. 1. Nucleotide sequence of rOCTN1 cDNA and predicted
amino acid sequence.
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Fig. 2. Comparison of amino acid sequences among rat OCTN1, human OCTN1, rat OCTN2, and human OCTN2. Identical amino
acids are shown in black boxes and conservative substitutions are shown in gray boxes.
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varying size. The clone containing the longest cDNA
insert was selected for structural and functional anal-
ysis. The nucleotide sequence (GenBank accession
No. AF169831) and the deduced amino acid se-
quence of rOCTN1 cDNA are given in Fig. 1. The
cDNA is 2258 bp long with a 1662 bp long open
reading frame (including the termination codon).
The 5P- and 3P-untranslated regions are 71 bp and
525 bp long, respectively. The 3P-untranslated region
contains the poly(A) tail and the polyadenylation
signal (AATAA). The predicted protein consists of
553 amino acids and hydropathy analysis of the ami-
no acid sequence predicts 12 transmembrane do-
mains. When modeled as the previously known mem-
bers of the mammalian organic cation/anion
transporter family, both the amino terminus and
the carboxy terminus of the rOCTN1 protein are
located on the cytoplasmic side of the membrane.
The extracellular loop between transmembrane do-
mains 1 and 2 consists of 109 amino acids and con-
tains three putative N-glycosylation sites (Asn-57,
Asn-64, and Asn-91). The protein also contains a
single cAMP-dependent phosphorylation site in the
cytosolic C-terminal tail (Ser-536) and ¢ve protein
kinase C-dependent phosphorylation sites located in
the ¢rst, second, and third intracellular loops (Ser-
164, Ser-225, Ser-280, Ser-286, and Ser-323). The
predicted molecular mass of the protein is 62.4 kDa.
Within the family of organic cation/anion trans-
porters, there exists signi¢cant homology among dif-
ferent members of the family. Comparative analysis
of amino acid sequences indicates rat OCTN1 to
have signi¢cant homology to all members (Fig. 2).
Rat OCTN1 exhibits signi¢cant homology to human
OCTN1 (V85% identity, V91% similarity) and hu-
man OCTN2 (V71% identity, V82% similarity).
Rat OCTN1 is also homologous to rat OCTN2, ex-
hibiting V74% identity and V85% similarity. Com-
parison of rat OCTN1 with rat OCTs shows the
following homology: OCT1 (34% identity, 50% sim-
ilarity), OCT2 (32% identity, 49% similarity) and
OCT3 (28% identity, 48% similarity).
3.2. Functional characteristics of rOCTN1
The functional characteristics of rOCTN1 were
studied in a mammalian cell heterologous expression
system using the vaccinia virus expression technique.
rOCTN1 cDNA was functionally expressed in HRPE
cells using this technique and the transport function
was monitored by measuring the cellular uptake of
TEA, a prototypical organic cation. Endogenous
TEA uptake was assessed under identical conditions
using cells transfected with vector alone. Uptake was
measured in an Na-free medium at pH 7.5. Uptake
of TEA (20 WM) was found to be several-fold higher
in rOCTN1 cDNA-transfected cells than in vector-
transfected cells (Fig. 3, upper panel). When the
cDNA-speci¢c uptake alone was considered, the up-
take was linear at least up to 60 min (Fig. 3, lower
panel). At 60 min, the increase in uptake in cDNA-
transfected cells over vector-transfected cells was
4.5-fold. The cDNA-speci¢c uptake was found to
be in£uenced signi¢cantly by the pH of the uptake
medium. The uptake increased gradually when the
pH of the medium was changed from 6.5 to 8.0
(Fig. 4). When the pH was increased further to 8.5,
Fig. 3. Time course of TEA transport in HRPE cells trans-
fected with either rOCTN1 cDNA (a) or pSPORT vector (b).
Transport of 20 WM [14C]TEA was measured at pH 8.0 in an
Na-free uptake medium (NMDG chloride was used to replace
NaCl iso-osmotically). TEA transport mediated speci¢cally by
rOCTN1 (R) was calculated by subtracting transport measured
in pSPORT-transfected cells from transport measured in
rOCTN1 cDNA-transfected cells.
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the uptake decreased. Based on these data, subse-
quent uptake measurements were made at pH 8.0
using a 15 min incubation period.
The speci¢city for organic cations for the transport
process mediated by rOCTN1 was studied using
competition experiments in which the ability of var-
ious unlabeled organic cations (1 or 5 mM) to com-
pete with [14C]TEA for the uptake process was as-
sessed (Table 1). 5-(N,N-dimethyl)amiloride (DMA),
desipramine, cimetidine, procainamide and verapamil
were found to be the most potent inhibitors, causing
80^90% inhibition. Nicotine, imipramine and 1-
methyl-4-phenylpyridinium (MPP) showed moderate
inhibition (40^70%), whereas choline, guanidine and
amiloride were the least e¡ective inhibitors (3^
20%). These data indicate a broad speci¢city for
rOCTN1 in the transport of organic cations. We
then studied the dose^response relationship for the
inhibition of rOCTN1-mediated TEA uptake by the
potent inhibitors DMA, desipramine, cimetidine
and procainamide (Fig. 5). The order of inhibitory
potency was: desipraminesDMAs procainamides
cimetidine. The IC50 values (concentration of com-
pounds necessary to cause 50% inhibition of TEA
Fig. 4. In£uence of pH on rOCTN1-mediated TEA transport.
Transport of 20 WM [14C]TEA was measured in rOCTN1
cDNA-transfected HRPE cells and in pSPORT vector-trans-
fected HRPE cells in parallel at di¡erent pH in the absence of
Na for 15 min. Data represent rOCTN1-speci¢c transport, cal-
culated by subtracting transport in vector-transfected cells from
transport in cDNA-transfected cells.
Table 1
Inhibition of rOCTN1-mediated TEA uptake by various organ-
ic cations
Inhibitor [14C]TEA transport
pmol/106 cells/15 min %
Control 65.41 þ 6.13 100
Choline (5 mM) 63.10 þ 1.73 97
Cimetidine (5 mM) 10.91 þ 5.57 17
Guanidine (5 mM) 64.30 þ 9.12 98
MPP (5 mM) 40.61 þ 5.63 62
Nicotine (5 mM) 19.12 þ 2.76 29
Procainamide (5 mM) 12.87 þ 6.68 20
Verapamil (5 mM) 13.25 þ 4.22 20
Amiloride (1 mM) 51.56 þ 3.32 79
Imipramine (1 mM) 19.92 þ 0.41 31
Desipramine (1 mM) 10.49 þ 1.13 16
DMA (1 mM) 4.04 þ 0.37 6
HRPE cells were transfected with rOCTN1 cDNA. [14C]TEA
(20 WM) transport in these cells was measured for 15 min in
the absence of Na and in the absence or presence of indicated
concentrations of various unlabeled organic cations. Transport
measured in vector-transfected cells was subtracted from trans-
port in cDNA-transfected cells to calculate rOCTN1-speci¢c
transport.
Fig. 5. Dose^response relationship for the inhibition of
rOCTN1-mediated transport of [14C]TEA by various organic
cations. Transport of 20 WM [14C]TEA was measured in
rOCTN1-expressing HRPE cells at pH 8.0 in an Na-free me-
dium for 15 min in the absence or presence of increasing con-
centrations of desipramine (R), DMA (O), procainamide (a),
TEA (S), and cimetidine (b). Transport was adjusted for en-
dogenous transport activity (i.e. transport in vector-transfected
cells) to determine rOCTN1-speci¢c transport. Transport in the
absence of inhibitors was taken as control (100%).
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uptake) for these compounds were 0.08 þ 0.01,
0.18 þ 0.01, 0.86 þ 0.16, and 1.54 þ 0.20 mM, respec-
tively. The dose^response relationship was also
studied for TEA by assessing the inhibition of the
uptake of [14C]TEA by increasing concentrations of
unlabeled TEA. Unlabeled TEA was found to com-
pete with [14C]TEA for the uptake process with an
IC50 value of 0.96 þ 0.10 mM.
3.3. Interaction of carnitine with rat OCTN1
The functional studies described thus far show
convincingly that rOCTN1 is an organic cation
transporter. However, OCTN1 is structurally related
closer to OCTN2 than to OCT1, OCT2 and OCT3.
While OCT1, OCT2 and OCT3 function only as
Na-independent organic cation transporters,
OCTN2 functions as a Na-independent organic cat-
ion transporter as well as an Na-dependent carni-
tine transporter [7,14,15,20]. This is true with
OCTN2 cloned from di¡erent animal species (hu-
man, rat, and mouse) [15,20]. Therefore, we investi-
gated in the present study the interaction of carnitine
with rat OCTN1. The uptake of [14C]TEA mediated
by rat OCTN1 was measured in the presence and
absence of Na and the in£uence of carnitine on
this uptake was assessed (Fig. 6). In the absence of
Na, carnitine was found to inhibit rOCTN1-medi-
ated TEA uptake to a signi¢cant extent, but only at
concentrations s 1 mM. Interestingly, the inhibitory
potency was weaker in the presence of Na. Thus,
carnitine does appear to interact with rOCTN1,
though with a low a⁄nity, but the interaction does
not require Na. These data are di¡erent from those
obtained with OCTN2 in our previous studies
[15,20]. OCTN2 transports TEA in the presence as
well as in the absence of Na as does rOCTN1, but
the ability of carnitine to inhibit OCTN2-mediated
TEA uptake is markedly potentiated in the presence
of Na, indicating that the interaction of carnitine
with OCTN2 is Na-dependent. In contrast, the in-
teraction of carnitine with rOCTN1 is Na-inde-
pendent. We then investigated the ability of rOCTN1
to transport carnitine (Table 2). The uptake of car-
Fig. 6. In£uence of carnitine on rOCTN1-mediated TEA trans-
port in the presence or absence of Na. Transport of 20 WM
[14C]TEA was measured in rOCTN1-expressing HRPE cells at
pH 8.0 in a medium containing NaCl (a) or in a medium in
which NaCl was replaced iso-osmotically with NMDG chloride
(b) for 15 min. Measurements were made in the absence or
presence of increasing concentrations of carnitine. Transport
was adjusted for endogenous transport activity (i.e. transport in
vector-transfected cells) to determine rOCTN1-speci¢c trans-
port. Transport in the absence of carnitine was taken as control
(100%).
Table 2
Comparison of carnitine transport in vector-transfected HRPE cells and rOCTN1 cDNA-transfected HRPE cells
Carnitine concentration Carnitine transport (pmol/106 cells/15 min)
Na-free medium Na-containing medium
pSPORT rOCTN1 cDNA pSPORT rOCTN1 cDNA
2.5 WM 11 þ 1 11 þ 1 23 þ 1 22 þ 2
0.5 mM 2697 þ 107 2897 þ 107 2690 þ 216 3207 þ 78
1 mM 4610 þ 341 4480 þ 169 4887 þ 560 4073 þ 463
HRPE cells were transfected with either pSPORT vector alone or rOCTN1 cDNA. Carnitine transport in these cells was measured
for 15 min in the presence and absence of Na. Uptake bu¡ers contained indicated concentrations of carnitine along with 20 nM
[3H]carnitine.
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nitine in control cells and in rOCTN1-expressing
cells was compared in the presence and absence of
Na at three di¡erent concentrations of carnitine. At
all three concentrations (2.5 WM, 0.5 mM, and
1 mM), there was no detectable level of carnitine
transport that was mediated by rOCTN1.
Taken collectively, these results show that
rOCTN1 is an organic cation transporter and that,
though structurally related to OCTN2 very closely,
rOCTN1 does not mediate Na-coupled carnitine
transport to any signi¢cant level.
3.4. Tissue distribution pattern of OCTN1 mRNA in
the rat
Northern blot analysis was carried out with poly-
(A) RNA isolated from 12 di¡erent tissues from the
rat to determine the tissue distribution pattern of
OCTN1 in rat (Fig. 7). The OCTN1-speci¢c tran-
scripts are detectable in a wide variety of tissues
with abundant expression in the intestine, liver, and
kidney. Comparatively lower levels of expression are
evident in the brain, thymus, lung, heart, spleen, and
skin. The transcripts are below detectable levels in
the skeletal muscle, stomach, and testis. There are
two distinct transcripts that are 2.5 kb and 3.2 kb
in size. The 2.5 kb transcript is present in all of the
positive tissues whereas the levels of expression of the
3.2 kb transcript vary among these tissues. Maximal
expression of the 3.2 kb transcript is seen in the liver.
We then performed in situ hybridization with tis-
sue sections from rat brain, kidney, heart, and pla-
centa using a rat OCTN1-speci¢c antisense riboprobe
to determine the regional distribution of OCTN1
mRNA in these tissues (Fig. 8). In the brain,
OCTN1 mRNA is most abundantly expressed in cer-
ebellum, especially in the granular layer. Lesser, but
detectable, levels of expression are also seen in the
molecular layer of the cerebellum. The expression at
low levels is also detectable throughout the cerebral
cortex and in the cornu ammonis pyramidal neurons
of the hippocampus. In the kidney, the expression is
evident in the cortical layer as well as in the medul-
lary layer, but the expression is most abundant in the
outer stripe of the outer medulla. The glomeruli are
also positive for OCTN1 expression. Even though
the mRNA is detectable in the absorptive cells of
both proximal and distal tubules, the expression is
more prominent in the straight portion of the prox-
imal tubules. In the heart, OCTN1 mRNA expres-
sion is seen in the myocardium, lamina ¢brosa of the
heart valves and the blood vessels. In the placenta,
expression is detectable throughout the labyrinthine
zone where it is found in the villous structures sur-
rounding the lacuna ¢lled with maternal blood. Very
low levels of expression are also seen in the visceral
yolk sac and chorionic plate. There were no detect-
able hybridization signals in any of these tissues
when a rat OCTN1-speci¢c sense riboprobe was
used instead of the antisense riboprobe (data not
shown).
4. Discussion
OCTN1 was originally cloned from human liver
[6]. The human OCTN1 was found to be structurally
related to the known members of the organic cation
transporter family, but the homology was much less
compared to the homology found among the known
members of the family. This led the investigators
Fig. 7. Northern blot analysis of rOCTN1-speci¢c transcripts in
rat tissues. The upper panel is the hybridization signals ob-
tained with the rOCTN1 cDNA probe and the lower panel is
the hybridization signals obtained with the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) cDNA probe. Lanes 1^12
represent brain, thymus, lung, heart, skeletal muscle, stomach,
small intestine, liver, kidney, spleen, testis, and skin, respec-
tively.
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who cloned the transporter to name OCTN1 as a
novel organic cation transporter. Human OCTN1
served as a probe in the isolation of a second human
novel organic cation transporter OCTN2 [7].
hOCTN1 and hOCTN2 are very closely related to
each other in primary structure. Thus, these two
members constitute a distinct subfamily within the
group of organic cation transporters. The remaining
members (OCT1, OCT2, and OCT3) form another
subfamily based on the primary structure.
The transport function of hOCTN1 has been
studied in detail [6,13]. It mediates the transport of
a wide variety of organic cations in a pH-dependent
manner. The transport process is electroneutral as
evidenced from the lack of any detectable e¡ect of
K-induced membrane depolarization on hOCTN1-
mediated transport of organic cations in Xenopus
laevis oocytes expressing hOCTN1 heterologously
[13]. It is believed that OCTN1 may be the organic
cation/H antiporter that has been described in the
kidney brush border membrane vesicles [13]. Interest-
ingly, hOCTN1 also transports carnitine, a zwitter-
ion, but whether this transport occurs via an Na-
coupled process or the cation species of carnitine is
preferentially transported has not been investigated
[13].
The present investigation was undertaken to eluci-
date the structure, function, and tissue distribution
pattern of the rat homolog of OCTN1. To date,
OCTN1 has not been cloned from any animal species
other than human. Since most of the information
available in the literature on the characteristics of
organic cation transport in the kidney or other tis-
sues has been derived using the rat as the animal
model, elucidation of the structure, function, and
tissue distribution of OCTN1 in the rat is of impor-
tance for comparative purposes. The results of the
present investigation show that rat OCTN1 is struc-
turally very close to human OCTN1 and that rat
OCTN1 interacts with a wide variety of organic cat-
ions as does human OCTN1. However, there are
some signi¢cant di¡erences between rat and human
OCTN1 in substrate speci¢city. Rat OCTN1 does
not interact with choline whereas human OCTN1
does. Verapamil exhibits much higher a⁄nity for hu-
man OCTN1 than for rat OCTN1. Similarly, there
are also di¡erences in the interaction of carnitine
with these two transporter homologs. The transport
of TEA mediated by human OCTN1 is inhibited by
carnitine with an IC50 (i.e. concentration needed for
50% inhibition) of 6 1 mM in the presence of Na.
Moreover, human OCTN1 recognizes carnitine as a
transportable substrate. In contrast, rat OCTN1 in-
teracts with carnitine with a very low a⁄nity. In the
presence of Na, carnitine at a concentration of
1 mM does not inhibit rat OCTN1-mediated TEA
transport. A signi¢cant inhibition is observed how-
ever at carnitine concentrations s 1 mM. Interest-
ingly, the carnitine-induced inhibition is greater in
the absence of Na than in the presence of Na.
This shows that the interaction of rat OCTN1 with
carnitine is not Na-dependent. In addition, even
though carnitine interacts with rat OCTN1 at high
concentrations as assessed by the ability of carnitine
to inhibit TEA transport mediated by rat OCTN1,
carnitine is not a transportable substrate for this
transporter. In the presence as well as in the absence
of Na, there was no detectable carnitine transport
via rat OCTN1. This was not due to the low a⁄nity
of the transporter for carnitine because the transport
measurements were made at a wide range of carnitine
concentrations. We conclude that rat OCTN1 does
6
Fig. 8. Detection of OCTN1 mRNA transcripts in rat tissues by in situ hybridization with rOCTN1-speci¢c digoxigenin-labeled anti-
sense riboprobe. A and B (low power and high power, respectively) represent hybridization signals in the brain. Positive signals are
evident in cortex (C), cornu ammonis pyramidal neurons of hippocampus (CA) and granular (G) and molecular (ML) layers of cere-
bellum (CB). C and D (low power and high power, respectively) represent hybridization signals in the kidney. Expression is positive
in cortex (Cx) and medulla (M), with highest levels of expression in the outer stripe of the outer medulla. Positive signals are present
in glomeruli (G) and in proximal and distal tubules. E and F (low power and high power, respectively) represent hybridization signals
in the heart. Positive signals are seen in myocardium (Myo) and in lamina ¢brosa of heart valves (AoV). Expression is evident
throughout the myocardium as well as in intermuscular arterioles (arrowhead). H, I, and J represent hybridization signals in the pla-
centa and G represents hematoxylin-eosin staining of the placenta. Positive signals are detectable in the labyrinthine zone (Lb) and
the signals are comparatively much weaker in the venous sinusoids (Vs) and in the chorionic plate (Ch). Expression is abundant in
the villous structures surrounding the lacuna ¢lled with maternal blood (arrows in I and asterisk in J).
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not transport carnitine and that it does exhibit sig-
ni¢cant di¡erences in substrate speci¢city with hu-
man OCTN1.
The present studies describe, for the ¢rst time, the
tissue distribution pattern of OCTN1. The signals
obtained with the rat OCTN1 probes in Northern
blot analysis and in in situ hybridization analysis
are speci¢c and do not represent cross-hybridization
with OCTN2 mRNA due to sequence homology.
This is supported by the following reasonings and
observations. First, hybridization was carried out
under high stringency conditions and therefore it is
unlikely that the probes cross-hybridize with OCTN2
mRNA. Second, the predominant signal in Northern
blot analysis is 2.5 kb in size in the case of OCTN1
in contrast to the 3.0 kb predominant signal for rat
OCTN2 [21]. Furthermore, the tissue distribution
pattern is quite di¡erent for OCTN1 (present study)
and OCTN2 [21] in rat tissues. OCTN1 is expressed
most abundantly in the intestine, liver, and kidney
whereas OCTN2 is expressed most abundantly in the
testis, colon, kidney and liver. Only a weak expres-
sion is noted in the intestine for OCTN2. Third,
there are signi¢cant di¡erences in the regional distri-
bution pattern of OCTN1 mRNA and OCTN2
mRNA in rat tissues. The present study shows that
OCTN1 mRNA is expressed in the rat kidney more
abundantly in the cortico-medullary junction than in
the cortex, suggesting a preferential expression in the
proximal straight tubules. On the other hand,
OCTN2 mRNA is expressed primarily in the cortical
region, suggesting a preferential expression in the
proximal and distal convoluted tubules [15]. In addi-
tion, OCTN2 mRNA is present at much higher levels
in the Purkinje cell bodies than other regions in the
cerebellum [15] while no such di¡erential expression
is noted in the Purkinje cell bodies for OCTN1
mRNA (present study).
OCTN1 is expressed very abundantly in the intes-
tine, kidney and liver where it is likely to play a role
in the handling of xenobiotics. The observed ¢ndings
that OCTN1 is also expressed in the brain and the
placenta are of pharmacological importance because
of the ability of OCTN1 to interact with a broad
spectrum of pharmacologically active drugs. This
suggests that OCTN1 might in£uence the disposition
of various drugs in these tissues. It is not clear
whether OCTN1 participates in the in£ux of drugs
into the cells or in the e¥ux of drugs out of the cells.
If OCTN1 is indeed an organic cation/H antiporter
as has been suggested for human OCTN1, this trans-
porter is likely to participate in the e¥ux of drugs. It
is however to be noted that such an e¥ux process is
expected to be located in the brush border membrane
of the placental trophoblast. But, our previous stud-
ies have failed to detect an organic cation/H anti-
port process for TEA, an OCTN1 substrate, in hu-
man placental brush border membrane vesicles
[22,23]. Furthermore, Northern blot analysis and in
situ hybridization studies show that OCTN1 is ex-
pressed widely in di¡erent organs. But, the organic
cation/H antiport process has been demonstrated
primarily in the kidney, liver, intestine and placenta
[24,25]. An additional ¢nding relevant to this issue is
the expression of OCTN1 predominantly in the junc-
tional zone between the medulla and the cortex in the
kidney. Drug elimination via the organic cation/H
antiport process occurs predominantly in the proxi-
mal convoluted tubules that are located in the cortex
[24,25]. More studies are needed to establish un-
equivocally whether or not OCTN1 is an organic
cation/H antiporter.
OCTN2, which is very closely related to OCTN1
in amino acid sequence, is an Na-independent or-
ganic cation transporter as well as an Na-dependent
carnitine transporter. It is clear that OCTN1 is an
Na-independent organic cation transporter.
Whether or not OCTN1 is an Na-dependent trans-
porter for any physiological substrate remains to be
seen. Interestingly, the tissue distribution pattern of
OCTN1 and OCTN2 is strikingly similar with some
notable exceptions. While the distribution pattern of
mRNA is exactly the same for both transporters in
the placenta and heart, there are signi¢cant di¡eren-
ces in the regional distribution of mRNA for these
transporters in the kidney and brain ([15], present
study). The physiological and pharmacological impli-
cations of the observed similarities and di¡erences in
the tissue distribution pattern and substrate speci¢c-
ity of the two closely related transporters OCTN1
and OCTN2 remain to be seen.
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